FDA Obesity panel impressed as Orexigen follows wise counsel and checks reality
This article was originally published in Scrip
Executive Summary
In a year that saw its two biotech rivals fail to achieve a positive recommendation from US FDA advisory panels for their obesity drugs, and one that saw pharmaceutical drugs for obesity withdrawn from the market, Orexigen Therapeutics rescued obesity from the stigma of being a graveyard indication by answering a question that the FDA wanted answering even though they did not explicitly demand it.